Patents by Inventor Seung Jin Ma

Seung Jin Ma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
    Patent number: 8513302
    Abstract: The invention provides uses and methods for reducing nephropathy in persons with diabetes mellitus (particularly Type 2 diabetes), in persons with metabolic syndrome, in persons with triglyceride levels over 215 mg/dL, and in persons with a cholesterol level over 200 mg/dL, by administering an inhibitor of soluble epoxide hydrolase (“sEH”). Optionally, a cis-epoxyeicosantrienoic acid (“EET”) can be administered with the sEH inhibitor. The invention further provides for using EETs in conjunction with one or more sEH inhibitors to reduce hypertension, and for compositions of EETs coated with a material insoluble in an acid of pH 3 but soluble in a solution with a pH of 7.4 or higher.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: August 20, 2013
    Assignee: The Regents of the University of California
    Inventors: Bruce D. Hammock, Takaho Watanabe, Seung-Jin Ma, Susan E. Bennett, Judith S. Stern, Christophe Morisseau, In-Hae Kim
  • REDUCING NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND EPOXYEICOSANOIDS
    Publication number: 20110269831
    Abstract: The invention provides uses and methods for reducing nephropathy in persons with diabetes mellitus (particularly Type 2 diabetes), in persons with metabolic syndrome, in persons with triglyceride levels over 215 mg/dL, and in persons with a cholesterol level over 200 mg/dL, by administering an inhibitor of soluble epoxide hydrolase (“sEH”). Optionally, a cis-epoxyeicosantrienoic acid (“EET”) can be administered with the sEH inhibitor. The invention further provides for using EETs in conjunction with one or more sEH inhibitors to reduce hypertension, and for compositions of EETs coated with a material insoluble in an acid of pH 3 but soluble in a solution with a pH of 7.4 or higher.
    Type: Application
    Filed: May 4, 2011
    Publication date: November 3, 2011
    Applicant: The Regents of the University of California
    Inventors: Bruce D. Hammock, Takaho Watanabe, Seung-Jin Ma, Susan E. Bennett, Judith S. Stern, Christophe Morisseau, In-Hae Kim
  • USE OF CIS-EPOXYEICOSANTRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO REDUCE PULMONARY INFILTRATION BY NEUTROPHILS
    Publication number: 20100317733
    Abstract: It has now been discovered that inhibitors of soluble epoxide hydrolase (“sEH”) are useful in reducing the severity of or inhibiting the progression of obstructive pulmonary diseases, restrictive airway diseases, and asthma. Administering a cis-epoxyeicosantrienoic acid (“EET”) in addition to the inhibitor is at least additive, and may be synergistic, in reducing or inhibiting these conditions and diseases, as measured by reduced numbers of neutrophils present in the lung. The inhibitor of sEH may be a nucleic acid, such as a small interfering RNA.
    Type: Application
    Filed: February 6, 2009
    Publication date: December 16, 2010
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Bruce D. Hammock, Kent E. Pinkerton, Kevin R. Smith, Takaho Watanabe, Seung Jin Ma
  • Reducing Nephropathy with Inhibitors of Soluble Epoxide Hydrolase and Epoxyeicosanoids
    Publication number: 20090018092
    Abstract: The invention provides uses and methods for reducing nephropathy in persons with diabetes mellitus (particularly Type 2 diabetes), in persons with metabolic syndrome, in persons with triglyceride levels over 215 mg/dL, and in persons with a cholesterol level over 200 mg/dL, by administering an inhibitor of soluble epoxide hydrolase (“sEH”). Optionally, a cis-epoxyeicosantrienoic acid (“EET”) can be administered with the sEH inhibitor. The invention further provides for using EETs in conjunction with one or more sEH inhibitors to reduce hypertension, and for compositions of EETs coated with a material insoluble in an acid of pH 3 but soluble in a solution with a pH of 7.4 or higher.
    Type: Application
    Filed: March 16, 2005
    Publication date: January 15, 2009
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Bruce D Hammock, Takaho Watanabe, Seung Jin Ma, Susan E. Bennett, Judith S. Stern, Christophe Morisseau, In-Hae Kim